• Users Online: 250
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
Ahead of Print

On X-linked hypophosphatemia at the European society of pediatric endocrinology meeting, Vienna, Austria; September 19–21, 2019

1 Pediatric Endocrinology and Diabetes Unit, Sultan Qaboos University Hospital, Muscat, Oman; Department of Pediatric, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, England, UK
2 Department of Pediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, England, UK
3 Department of Endocrinology and Diabetes for Children, Bicetre Paris Sud Hospital, Paris, France

Correspondence Address:
Hussain Alsaffar,
Sultan Qaboos University Hospital, P. O. Box 38, Al-Khod, Muscat

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijmbs.ijmbs_3_20

X-linked hypophosphatemia (XLH) is the most common form of inherited hypophosphatemic rickets. Phosphate wasting results in weak, soft and deformed bones, impaired growth, and affected mobility. It is mainly caused by a loss of function mutation in PHEX gene that leads to elevated fibroblast growth factor-23 which mediates the phosphate wasting. During the 58th annual meeting of the European Society of Pediatric Endocrinology (ESPE) held in Vienna between September 19, 2019 and 21, 2019, nearly 100 free communications and a dedicated symposium focused on XLH. The authors attended the conference and wished to share its highlights pertaining to XLH and burosumab therapy to extend the benefit to other professionals who did not attend.

Print this article
  Search Pubmed for
    -  Alsaffar H
    -  Senniappan S
    -  Linglart A
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded7    

Recommend this journal